<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04900155</url>
  </required_header>
  <id_info>
    <org_study_id>PSU/T-487</org_study_id>
    <nct_id>NCT04900155</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effect of Long-term Lipid-lowering Therapy in STEMI Patients With Coronavirus Infection COVID-19</brief_title>
  <acronym>CONTRAST-3</acronym>
  <official_title>Evaluation of Long-term Lipid-lowering Therapy on Myocardial Electrical Heterogeneity, Myocardial Deformation, Arterial Stiffness and Quality of Life in Patients With Primary STEMI/NSTEMI With Coronavirus Infection COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Penza State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Penza State University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is planned to include 200 patients hospitalized with primary myocardial infarction with&#xD;
      and without ST segment elevation (STEMI or NSTEMI) in combination with COVID-19 within the&#xD;
      first 15 days from the disease onset. The total follow-up period is 96 weeks.&#xD;
&#xD;
      Hypotheses:&#xD;
&#xD;
        1. An integrated approach in assessing myocardial contractility, regulation of the heart&#xD;
           and the structural and functional state of arteries will make it possible to more&#xD;
           accurately assess the heart pumping function; explain the mechanisms of the relationship&#xD;
           between left ventricular (LV) contractile function and its volumetric indices; to study&#xD;
           the mechanisms of ventriculo-arterial coupling and the influence of autonomic&#xD;
           regulation, the role of markers of the sudden cardiac death (late ventricular&#xD;
           potentials, pathological turbulence of the heart rate, dispersion of the QT interval).&#xD;
&#xD;
        2. In patients who have had myocardial infarction in combination with the new coronavirus&#xD;
           infection SARS-CoV-2 (COVID-19), long-term highly effective lipid-lowering therapy,&#xD;
           regardless of the drugs prescribed, has an antiarrhythmic effect and has a beneficial&#xD;
           effect on the autonomic regulation of the heart rate. Highly effective lipid-lowering&#xD;
           therapy leads to an improvement in LV contractility and structural and functional&#xD;
           properties of the large arteries.&#xD;
&#xD;
      Methods and variables&#xD;
&#xD;
        1. Office blood pressure&#xD;
&#xD;
        2. 12-lead ECG&#xD;
&#xD;
        3. Coronary angiography. Percutaneous coronary intervention&#xD;
&#xD;
        4. Chemistry blood test&#xD;
&#xD;
        5. 2D and 3D transthoracic echocardiography (Vivid GE 95 Healthcare (USA)&#xD;
&#xD;
        6. Multi-day 3-lead ECG monitoring with assessment of the parameters of myocardial&#xD;
           electrical instability.&#xD;
&#xD;
        7. Ultrasound of common carotid arteries using high-frequency radio-frequency signal&#xD;
           technology&#xD;
&#xD;
        8. Applanation tonometry (SphygmoCor, AtCor, Australia)&#xD;
&#xD;
        9. Assessment of the arterial stiffness by volume sphygmography.&#xD;
&#xD;
       10. Flow-mediated vasodilation&#xD;
&#xD;
       11. Six-minute walk test&#xD;
&#xD;
       12. Computer pulse oximetry (PulseOx 7500 (SPO medical, Israel)&#xD;
&#xD;
       13. Adherence to Treatment: Counting remaining pills and completing the Morisky-Green&#xD;
           Questionnaire&#xD;
&#xD;
       14. Assessment of quality of life&#xD;
&#xD;
       15. Assessment of physical activity: International Questionnaire On Physical Activity - IPAQ&#xD;
&#xD;
       16. Hospital Anxiety and Depression Scale (HADS)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is planned to include 200 patients hospitalized in the cardiology department of the &quot;Penza&#xD;
      Regional Clinical hospital Burdenko&quot; with a STEMI diagnosis in combination with COVID-19.&#xD;
      Patients with STEMI and NSTEMI will be included in the study within the first 15 days from&#xD;
      the disease onset. The total follow-up period is 96 weeks.&#xD;
&#xD;
      Primary goals:&#xD;
&#xD;
        -  achieving the target level of low-density lipoprotein cholesterol (LDL-C) on the&#xD;
           background of lipid-lowering therapy as monotherapy with atorvastatin or combined&#xD;
           treatment with atorvastatin plus ezetimibe;&#xD;
&#xD;
        -  decrease in the incidence of major coronary events - percutaneous coronary interventions&#xD;
           (PCI) / coronary artery bypass surgery (CABG) for a new case of coronary&#xD;
           atherosclerosis, hospitalization for unstable angina or recurrent myocardial infarction;&#xD;
&#xD;
        -  reduction of the frequency of life-threatening arrhythmias and markers of the risk of&#xD;
           sudden cardiac death according to the data of long-term ECG monitoring;&#xD;
&#xD;
        -  increase in myocardial contractility by improving the deformation characteristics of the&#xD;
           peri-infarction zone.&#xD;
&#xD;
      Secondary goals:&#xD;
&#xD;
        1. Assess the effect of long-term effective lipid-lowering therapy:&#xD;
&#xD;
             -  indicators of global and regional myocardial deformation, depending on the degree&#xD;
                of of coronary blood flow restoration according to TIMI scale;&#xD;
&#xD;
             -  systolic and diastolic LV function in the presence of initial disturbances or the&#xD;
                absence of negative dynamics of these indicators with normal initial values;&#xD;
&#xD;
             -  on clinical and diagnostic criteria for the development or progression of heart&#xD;
                failure (HF);&#xD;
&#xD;
             -  on the dynamics of myocardial ischemia episodes according to the data of long-term&#xD;
                electrocardiography (ECG) monitoring;&#xD;
&#xD;
             -  for the immediate and long-term prognosis of patients;&#xD;
&#xD;
             -  on the structural and functional properties of large arteries.&#xD;
&#xD;
        2. Assess the dynamics of biochemical parameters against the background of double and&#xD;
           monotherapy with lipid-lowering drugs.&#xD;
&#xD;
        3. Assess the safety of treatment.&#xD;
&#xD;
        4. Assess the impact on the patient's well-being and quality of life.&#xD;
&#xD;
        5. Assess therapy compliance&#xD;
&#xD;
        6. Conduct a comparative analysis of the prognostic value of markers of myocardial&#xD;
           electrical heterogeneity, obtained from the data of long-term and 24-hour ECG&#xD;
           monitoring.&#xD;
&#xD;
        7. To determine the effect of markers of electrical instability and autonomic regulation of&#xD;
           cardiac activity, obtained during long-term ECG monitoring in patients at different&#xD;
           times after myocardial infarction, on the short-term and long-term prognosis.&#xD;
&#xD;
        8. Development of a multivariate model that takes into account the parameters of&#xD;
           electrophysiological heterogeneity and the main indicators of the cardiovascular system&#xD;
           condition (data of echocardiography, blood vessels ultrasound, laboratory test), which&#xD;
           allows predicting the development of repeated cardiac events.&#xD;
&#xD;
      Methods and variables&#xD;
&#xD;
        1. Office blood pressure&#xD;
&#xD;
        2. 12-lead ECG&#xD;
&#xD;
        3. Coronary angiography. Percutaneous coronary intervention&#xD;
&#xD;
        4. Chemistry blood test The lipid profile: total cholesterol (TC), high-density lipoprotein&#xD;
           cholesterol (HDL-C), triglycerides (TG) and low-density lipoprotein cholesterol (LDL-C),&#xD;
           non-HDL. Alanine aminotransferase (ALT), aspartat aminotransferase (AST), creatine&#xD;
           phosphokinase (CPK), glucose, C-reactive protein (CRP), brain natriuretic peptide (BNP),&#xD;
           serum creatinine and glomerular filtration rate (CKD-EPI), troponin I/T, CPK-MB,&#xD;
           ferritin, sodium, potassium, lactate, procalcitonin, D-dimer, coagulogram.&#xD;
           Nasopharyngeal swab for SARS-CoV-2 to RNA by PCR, if necessary - additional&#xD;
           determination of immunoglobulins to SARS-CoV-2.&#xD;
&#xD;
        5. 2D and 3D transthoracic echocardiography is performed with Vivid GE 95 Healthcare (USA).&#xD;
           The biplane ejection fraction is determined by the Simpson method, 3D ejection fraction,&#xD;
           EDV (end-diastolic volume), ESV (end-systolic volume) and their indexed parameters in 2D&#xD;
           and 3D mode. Left ventricular myocardial mass index (LVMI), LA volume. Myocardial&#xD;
           deformity is analyzed using specialized software - EchoPac Software Only (General&#xD;
           Electric Co., 2018)&#xD;
&#xD;
        6. Multi-day 3-lead ECG monitoring with assessment of the parameters of myocardial&#xD;
           electrical instability.&#xD;
&#xD;
        7. Ultrasound of common carotid arteries using high-frequency RF signal technology will be&#xD;
           carried out in B-mode on the MyLab 90 device (Esaote, Italy) by the following&#xD;
           indicators: IMT - thickness of the intima-media, loc Psys - local systolic pressure in&#xD;
           the carotid artery, loc Pdia - local diastolic pressure, P (T1) - pressure at a local&#xD;
           point, stiffness indices β and α, DC - coefficient transverse distensibility, CC -&#xD;
           transverse compliance coefficient, Aix - augmentation index, AR - amplification&#xD;
           pressure, PWV - local pulse wave velocity in the carotid artery.&#xD;
&#xD;
        8. Applanation tonometry The SphygmoCor device (AtCor Medical, Australia) includes two&#xD;
           software. The first allows to record indicators of central aortic pressure: systolic&#xD;
           aortic pressure - SBPao, diastolic - DBPao, pulse pressure - PPao, mean hemodynamic&#xD;
           pressure - MBPao. The PWV (pulse wave velocity) software is used to analyze the PWV in&#xD;
           the aorta (cfPWV).&#xD;
&#xD;
        9. Assessment of the arterial stiffness by volume sphygmography. PWV in the aorta (PWV), in&#xD;
           elastic arteries right and left (R/L-PWV) and in muscular arteries (B-PWV), Cardio-Ankle&#xD;
           Vascular Index - CAVI.&#xD;
&#xD;
       10. Flow-mediated vasodilation&#xD;
&#xD;
       11. 6-minute walk test&#xD;
&#xD;
       12. Computer pulse oximetry (PulseOx 7500 (SPO medical, Israel)&#xD;
&#xD;
       13. Adherence to Treatment: Counting remaining pills and completing the Morisky-Green&#xD;
           Questionnaire&#xD;
&#xD;
       14. Assessment of quality of life: Seattle Angina Questionnaire (SAQ), Minnesota LIGE with&#xD;
           Heart Failure Questionnaire, Clinical Status Assessment Scale (CASA), analog-visual&#xD;
           scale.&#xD;
&#xD;
       15. Assessment of physical activity International Questionnaire On Physical Activity - IPAQ&#xD;
&#xD;
       16. Hospital Anxiety and Depression Scale (HADS)&#xD;
&#xD;
      Endpoint assessment The end point is understood as the development of repeated AMI, unstable&#xD;
      angina pectoris, PCI for a new atherosclerotic plaque, hospitalization due to chronic heart&#xD;
      failure (CHF) exacerbation, the development of a new case of CHF II-IV NYHA class, death.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2020</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lipid profile assessment</measure>
    <time_frame>up to 96 weeks</time_frame>
    <description>Achievement of target level of lipid profile (total cholesterol, LDL-С, HDL-C, triglycerides) during the atorvastatin therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of ventricular rhythm disturbances</measure>
    <time_frame>up to 96 weeks</time_frame>
    <description>The frequency of ventricular arrhythmias recorded with 24 hour ECG monitoring</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrical instability and autonomic regulation of heart rate</measure>
    <time_frame>up to 96 weeks</time_frame>
    <description>Changes in parameters of electrical instability and autonomic regulation of heart rate recorded with 24 hour ECG monitoring</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left ventricular systolic function</measure>
    <time_frame>up to 96 weeks</time_frame>
    <description>Assessment of LV systolic function differences according to echocardiography during atorvastatin treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left ventricular myocardial deformation (strain, strain rate)</measure>
    <time_frame>up to 96 weeks</time_frame>
    <description>Assessment of LV myocardial deformation (strain, strain rate) differences according to echocardiography during atorvastatin treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with major cardiovascular events</measure>
    <time_frame>up to 96 weeks</time_frame>
    <description>Number of Participants with major cardiovascular events: PCI / CABG for a new case of coronary atherosclerosis, hospitalizations for unstable angina pectoris, recurrent AMI</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>STEMI</condition>
  <condition>Covid19</condition>
  <condition>NSTEMI</condition>
  <arm_group>
    <arm_group_label>Atorvastatin 80 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Initially, hypolipidemic treatment with atorvastatin at a dose of 80 mg / day is prescribed from the first 24-96 hours of myocardial infarction in addition to standard therapy for the disease.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin-Ezetimibe</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the absence of reaching the target level of LDL-C ≤1.4 mmol / L and ≥50% of the initial level after 4-6 weeks from the onset of myocardial infarction, patients additionally receive ezetimibe at a dose of 10 mg 1 time / day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 80mg</intervention_name>
    <description>Initially, hypolipidemic treatment with atorvastatin at a dose of 80 mg / day is prescribed from the first 24-96 hours of myocardial infarction in addition to standard therapy for the disease.</description>
    <arm_group_label>Atorvastatin 80 mg</arm_group_label>
    <other_name>Atorvastatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin-Ezetimibe</intervention_name>
    <description>In the absence of reaching the target level of LDL-C ≤1.4 mmol / L and ≥50% of the initial level after 4-6 weeks from the onset of myocardial infarction, patients additionally receive ezetimibe at a dose of 10 mg 1 time / day.</description>
    <arm_group_label>Atorvastatin-Ezetimibe</arm_group_label>
    <other_name>Atorvastatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent&#xD;
&#xD;
          2. Patients of both genders aged 30 to 70 years&#xD;
&#xD;
          3. The presence of one of the options for a combination of confirmed myocardial&#xD;
             infarction and new coronavirus infection:&#xD;
&#xD;
        3.1. Myocardial infarction that developed within 30 days from the onset of COVID-19 - in&#xD;
        case of mild to moderate course or within 60 days - in case of severe course.&#xD;
&#xD;
        3.2. Development of a confirmed case of COVID-19 within 30 days from the myocardial&#xD;
        infarction onset.&#xD;
&#xD;
        4.1. Clinical manifestations of acute respiratory infection (body t&gt; 37.5 ° C and one or&#xD;
        more signs: cough, dry or moist sputum, shortness of breath, chest tightness, SpO2 ≤ 95%,&#xD;
        sore throat, mild or moderate rhinorrhea, impaired or loss of smell (hyposmia or anosmia),&#xD;
        loss of taste (dysgeusia), conjunctivitis, weakness, muscle pain, headache, vomiting,&#xD;
        diarrhea, skin rash) in the presence of at least one of the epidemiological signs:&#xD;
&#xD;
          -  returning from a foreign trip 14 days before the onset of symptoms;&#xD;
&#xD;
          -  having close contacts in the last 14 days with a person under surveillance for&#xD;
             COVID-19 who subsequently fell ill;&#xD;
&#xD;
          -  having close contacts in the last 14 days with a person with a laboratory confirmed&#xD;
             diagnosis of COVID-19;&#xD;
&#xD;
          -  having professional contacts with people who have a suspected or confirmed case of&#xD;
             COVID-19.&#xD;
&#xD;
        4.2. The presence of clinical manifestations specified in 4.1, in combination with changes&#xD;
        in the lungs according to computed tomography data, regardless of the results of a single&#xD;
        laboratory study for the presence of SARS-CoV-2 RNA and an epidemiological history, or if&#xD;
        it is impossible to conduct a laboratory study for the presence of SARS-RNA CoV-2.&#xD;
&#xD;
        4.3. A positive laboratory test result for the presence of SARS-CoV-2 RNA using nucleic&#xD;
        acid amplification methods (NAA) or SARS-CoV-2 antigen using immunochromatographic&#xD;
        analysis, regardless of clinical manifestations.&#xD;
&#xD;
        4.4. Positive result for IgA or IgM, or IgM with IgG in patients with clinically confirmed&#xD;
        COVID-19 infection.&#xD;
&#xD;
        Primary STEMI or NSTEMI, confirmed by a diagnostically significant increase in&#xD;
        cardiospecific enzymes (5.1) in combination with at least one criterion of acute myocardial&#xD;
        ischemia (item 5.2):&#xD;
&#xD;
        5.1. An increase and / or decrease of serum cardiac troponin level, which should at least&#xD;
        once exceed the 99th percentile of the URL in patients without an initial increase of serum&#xD;
        cardiac troponin level, or its increase&gt; 20% with an initially increased level of cardiac&#xD;
        troponin, if up to it remained stable (variation &lt; 20%) or declined.&#xD;
&#xD;
        5.2. Typical anginal attack / acute ischemic changes on the ECG / the appearance of&#xD;
        pathological Q waves on the ECG / EchoCG confirmation of the presence of new areas of the&#xD;
        myocardium with impaired local contractility / detection of intracoronary thrombosis in&#xD;
        coronary angiography.&#xD;
&#xD;
        Presence of type 1 myocardial infarction (6.1) or type 2 (6.2), confirmed by coronary&#xD;
        angiography:&#xD;
&#xD;
        6.1. Atherothrombosis of an infarct-related artery with a sharp decrease in blood flow&#xD;
        distal to the damaged atherosclerotic plaque or distal embolization with thrombotic masses&#xD;
        / fragments of atherosclerotic plaque, followed by the development of myocardial necrosis;&#xD;
        or intramural hematoma in a damaged atherosclerotic plaque with a rapid increase in its&#xD;
        volume and a decrease in the lumen of the artery).&#xD;
&#xD;
        6.2. Myocardial infarction developed as a result of ischemia caused by non-thrombotic&#xD;
        complications of coronary atherosclerosis. Pathophysiologically, such myocardial&#xD;
        infarctions are associated with an increase in myocardial oxygen demand and / or a decrease&#xD;
        in its delivery to the myocardium, for example, due to coronary artery embolism,&#xD;
        spontaneous coronary artery dissection, respiratory failure, anemia, cardiac arrhythmias,&#xD;
        arterial hypertension or hypotension, etc.&#xD;
&#xD;
        Duration of subsequent hospitalization after inclusion in the study - at least 5 days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hemodynamically significant stenosis of the left coronary artery&gt; 30%.&#xD;
&#xD;
          2. Recurrent or repeated STEMI or NSTEMI.&#xD;
&#xD;
          3. Exogenous hypertriglyceridemia (type 1 hyperchylomicronemia - TC / TG &lt;0.15).&#xD;
&#xD;
          4. Acute heart failure III-IV.&#xD;
&#xD;
          5. Individual intolerance to statins, ezetimibe, alirocumab.&#xD;
&#xD;
          6. Congenital and acquired heart defects.&#xD;
&#xD;
          7. Non-sinus rhythm, artificial pacemaker.&#xD;
&#xD;
          8. Sinoatrial and atrioventricular block of 2-3 degrees.&#xD;
&#xD;
          9. QRS complex&gt; 100 ms.&#xD;
&#xD;
         10. Complete blockade of left or right bundle branch.&#xD;
&#xD;
         11. History of CHF III-IV class according to NYHA.&#xD;
&#xD;
         12. The presence of pronounced LV hypertrophy according to echocardiography (IVS / LVS&gt; 14&#xD;
             mm).&#xD;
&#xD;
         13. Uncontrolled hypertension with SBP&gt; 180 mm Hg. and DBP&gt; 110 mm Hg.&#xD;
&#xD;
         14. Diabetes mellitus type 1 or type 2 requiring insulin therapy.&#xD;
&#xD;
         15. Presence of anemia at the time of screening (Hb &lt;100 g / l)&#xD;
&#xD;
         16. Chronic kidney disease (GFR &lt; 30 ml / min / 1.73 m2 according to the CKD-EPI formula).&#xD;
&#xD;
         17. Uncorrected thyroid dysfunction in the presence of hyper- / hypothyroidism.&#xD;
&#xD;
         18. Body mass index (BMI) ≥35 kg / m2.&#xD;
&#xD;
         19. Pregnancy, lactation.&#xD;
&#xD;
         20. Alcohol abuse, drug use.&#xD;
&#xD;
         21. Other severe concomitant diseases that exclude the possibility of participation in the&#xD;
             study.&#xD;
&#xD;
         22. Participation in other clinical trials within the previous 2 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valentin Oleynikov</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penza State University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Valentin Oleynikov, DM</last_name>
    <phone>+78412548229</phone>
    <email>V.oleynikof@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nadezhda Burko, PhD</last_name>
    <phone>89869366220</phone>
    <email>nsergatskaya@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Valentin Oleynikov</name>
      <address>
        <city>Penza</city>
        <zip>440026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valentin Oleynikov, Prof.</last_name>
      <phone>+78412548229</phone>
      <email>v.oleynikof@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Nadezhda Burko, PhD</last_name>
      <phone>+78412548229</phone>
      <email>hopeful.n@mail.ru</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 9, 2021</study_first_submitted>
  <study_first_submitted_qc>May 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2021</study_first_posted>
  <last_update_submitted>May 23, 2021</last_update_submitted>
  <last_update_submitted_qc>May 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Penza State University</investigator_affiliation>
    <investigator_full_name>Valentin Oleynikov</investigator_full_name>
    <investigator_title>Head of Therapy Department</investigator_title>
  </responsible_party>
  <keyword>myocardial strain</keyword>
  <keyword>arterial stiffness</keyword>
  <keyword>myocardial electrical heterogeneity</keyword>
  <keyword>quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Non-ST Elevated Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

